Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.
OBJECTIVE
To evaluate the effects of gliclazide on oxidative status and vascular response to systemic administration of L-arginine, the natural precursor of nitric oxide (NO), in Type 2 diabetic patients.


METHODS
Thirty Type 2 diabetic patients received glibenclamide (n = 15) or gliclazide (n = 15) in a 12-week, randomized, observer-blinded, parallel study. Plasma lipid peroxides, total radical-trapping anti-oxidant parameter (TRAP), and blood pressure responses to an intravenous bolus of L-arginine were measured pre- and post-treatment.


RESULTS
At 12 weeks, gliclazide patients had lower plasma lipid peroxides (13.3 +/- 3.8 micro mol/l vs. 19.2 +/- 4.3 micro mol/l; P = 0.0001) and higher plasma TRAP (1155.6 +/- 143.0 micro mol/l vs. 957.7 +/- 104.3 micro mol/l; P = 0.0001) than the glibenclamide patients. Gliclazide but not glibenclamide significantly reduced systolic and diastolic blood pressure (P = 0.0199 and P = 0.00199, respectively, two-way repeated measures analysis of variance) in response to intravenous L-arginine.


CONCLUSIONS
Gliclazide reduces oxidative stress in Type 2 diabetic patients by improving plasma anti-oxidant status. This effect is associated with enhanced NO-mediated vasodilation.
Fava
D
D
Department of Internal Medicine, University of Rome La Sapienza and National Institute of Nutrition, Rome, Italy.
Cassone-Faldetta
M
M
Laurenti
O
O
De Luca
O
O
Ghiselli
A
A
De Mattia
G
G
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000032:analysis; D001120:Arginine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005609:Free Radicals / Q000097:blood; D005907:Gliclazide / Q000627:therapeutic use*; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008054:Lipid Peroxides / Q000097:blood; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
D000975:Antioxidants; D005609:Free Radicals; D007004:Hypoglycemic Agents; D008054:Lipid Peroxides; D009569:Nitric Oxide; D001120:Arginine; D005907:Gliclazide; D005905:Glyburide